Abstract:Objective: The aim of this study is to assess the postoperative efficacy of the combined administration of dienogest (DNG) and gonadotropin-releasing hormone agonists (GnRH-a) in patients diagnosed with endometriosis (EMS), while acknowledging the extensive use of DNG in the extended therapeutic management of EMS. Methods: In this retrospective study, a cohort of 154 patients who underwent conservative surgical intervention for EMS were scrutinized. The cohort was stratified into two distinct groups based on their prescribed pharmacological regimens. Group A, 70 patients received postoperative oral administration of DNG at a dosage of 2 mg/day, whereas Group B, 84 patients underwent treatment involving 3 to 4 injections of GnRH-a post-surgery, followed by DNG therapy. Parameters assessed included pelvic pain visual analog scale (VAS) scores, quality of life metrics (EHP-5), and the incidence of adverse reactions within both groups. Results: Both groups exhibited sustained low VAS scores following the prescribed treatments. The predominant occurrence of adverse bleeding patterns manifested predominantly within the initial 6 months of the treatment. Notably, Group B demonstrated a significantly diminished of experiencing frequent and irregular bleeding in comparison to the DNG group (20.0% vs. 8.3%, 12.9% vs. 3.6%, p < 0.05). The administration of GnRH-a did not exacerbate the impact on bone health. Subsequent to health promotion interventions, the incidence of weight gain in both groups declined to 7.1% during the 6-month follow-up ( p < 0.05). Group B exhibited a 100% satisfaction rate with the treatment, concomitant with a noteworthy reduction in EHP-5 scores ( p < 0.05). Patients with deep infiltrating endometriosis (DIE) nodules displayed marginally higher postoperative VAS scores than their non-DIE counterparts (0.89 ± 0.96 vs. 0.49 ± 0.78). However, with sustained medication use, pain scores within the DIE group exhibited a continual decrease, maintaining a low level of 0.29 ± 0.67 at 12 months and beyond. Conclusion: The short-term adjunctive use of GnRH-a prior to DNG treatment postoperatively in patients with EMS proves efficacious in mitigating early adverse bleeding, enhancing patient adherence, and improving overall quality of life. Notably, this therapeutic approach demonstrates favorable safety profiles and is equally effective in patients with DIE.

Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial

The efficacy and safety of up to 24 weeks of triptorelin therapy following conservative surgery in patients with deep infiltrating endometriosis (DIE): a multicentre, prospective, non-interventional study in China

The Efficacy and Safety of Triptorelin-Therapy Following Conservative Surgery for Deep Infiltrating Endometriosis A Multicenter, Prospective, Non-Interventional Study in China

Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis Post-hoc analysis of a multicentre, prospective, real-world study

Effect of gonadotropin-releasing hormone agonist therapy after laparoscopic conservative surgery with moderate to severe endometriosis

Dienogest in conjunction with GnRH-a for postoperative management of endometriosis

2604 A Comparison of Efficacy Between Postoperative Medical Treatment and Expectant Treatment in Relieving Dysmenorrhea After Conservative Laparoscopic Surgery for Deep-Infiltrating Endometriosis Accompanied by Dysmenorrhea

Deep Infiltrating Endometriosis Treatment with Dienogest: A Pilot Study

Long-Term Administration of Dienogest for the Treatment of Pain and Intestinal Symptoms in Patients with Rectosigmoid Endometriosis

Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis

Efficacy of postsurgical medical therapy for infertile patients with deep endometriosis

Postoperative management of patients with endometriosis

Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis

Dienogest as a Maintenance Treatment for Endometriosis Following Surgery: A Systematic Review and Meta-Analysis

Outcomes of treatment with cyclic administration of dienogest after ovarian endometriotic cystectomy

A randomized, double‐blind, placebo‐controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis

Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability

Initiation of GnRH Agonist Treatment on 3-5 Days Postoperatively in Endometriosis Patients: a Randomized Controlled Trial.

Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study

EFFORT study: Comparing impact of operation and assisted reproductive technologies on fertility for women with deep infiltrating endometriosis – study protocol for a multicentre randomised trial

Clinical experience of long-term use of dienogest after surgery for ovarian endometrioma